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Background Hyperhomocysteinemia, an independent and 
graded risk factor for coronary artery disease (CAD), may 
result from both environmental and hereditary factors. Meth­
ylenetetrahydrofolate reductase (MTHFR) catalyzes the con­
version of methylenetetrahydrofolate to methyltetrahydrofo- 
late, the methyl donor in the remethylation of homocysteine to 
methionine. A 677C—>T mutation in the MTHFR gene has 
been associated with elevated homocysteine concentrations in 
homozygous (+ /+ )  individuals.
Methods and Results We assessed the frequency of this 
common mutation in 735 CAD patients from the Regression 
Growth Evaluation Statin Study (REGRESS), a lipid-lowering 
coronary-regression trial, and in 1250 population-based control 
subjects. Furthermore, the association between the mutation 
and serum homocysteine concentrations was studied. The 
frequency of the homozygous (+ /+ )  mutation was 9.5% among 
patients versus 8.5% among control subjects, resulting in an 
odds ratio of 1.21 (95% confidence interval [Cl], 0.87 to 1,68), 
relative to the (—/ —) genotype. Homocysteine concentrations
A  recent meta-analysis by Boushey et al1 of 27 independent studies in which plasma homocys­teine concentrations were quantitatively re­lated to atherosclerotic disease demonstrated that mild 
hyperhomocysteinemia is an independent and graded 
risk factor for cerebral, peripheral, and CAD. Elevated 
homocysteine concentrations may originate from nutri­
tional deficiencies in cofactors or cosubstrates of en­
zymes involved in homocysteine metabolism or from 
molecular defects in genes coding for enzymes crucial in 
this metabolism.2"5
The enzymes pivotal in homocysteine metabolism are 
CBS, the first enzyme in homocysteine transsulfuration,
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were significantly elevated in both (+ /+ )  and ( + / - )  individuals 
compared with (—/ —) individuals (median homocysteine levels, 
15.4, 13.4, and 12.6 jmmol/L, for (+ /+ ) ,  (+ / - ) ,  and ( - / —) 
individuals, respectively). For a summary estimation of the risk 
of the (+ /+ )  genotype for CAD, we performed a meta-analysis 
on 8 different case-control studies on thermolabile MTHFR in 
CAD, In the meta-analysis, the homozygous (+ /+ ) genotype 
was present in 299 of 2476 patients (12.1%) and in 257 (10.4%) 
of 2481 control subjects, resulting in a significant odds ratio of
1.22 (95% Cl, 1,01 to 1.47) relative to the ( - / - )  genotype.
Conclusions Both the homozygous (+ /+ )  and heterozygous 
( + /—) genotype result in elevated homocysteine concentra­
tions. From our meta-analysis, we conclude that the homozy­
gous (+ /+ )  genotype is a modest but significant risk factor for 
CAD. (Circulation. 1997;96:2573-2577.)
Key Words • homocysteine • methylenetetrahydrofolate 
reductase •  coronary disease •  meta-analysis • risk 
factors
and MTHFR, which is involved in the folic acid depen­
dent remethylation of homocysteine to methionine. 
Both genes have been cloned and characterized,6*7 and 
several mutations have been reported8-12 in patients with 
a homozygous deficient phenotype. Heterozygotes for 
either CBS or MTHFR deficiency often have elevated 
homocysteine concentrations. However, the frequency 
of heterozygosity for CBS and MTHFR deficiency is too 
low to account for the frequency of mildly elevated 
homocysteine levels in patients with cardiovascular 
disease.13
MTHFR is a flavoprotein that reduces 5,10-methy- 
lenetetrahydrofolate to 5-methyltetrahydrofolate, the 
predominant circulating form of folate. In 1988, Kang et 
al5 described a new MTHFR variant with thermolabile 
properties. Individuals with this MTHFR variant have 
decreased specific MTHFR activity in lymphocytes 
(<50% of the control mean), have increased thermo- 
lability after preincubation at 46°C, and may have ele­
vated plasma homocysteine concentrations. In other 
studies, the same group reported an increased incidence 
of this MTHFR variant in patients with CADU com­
pared with control subjects (17% versus 5%, respective­
ly), and they were able to correlate the incidence of 
thermolabile MTHFR to the severity of CAD.15 In a 
Dutch study, this thermolabile MTHFR was found to be 
the cause of abnormal homocysteine metabolism in 11 of 
39 hyperhomocysteinemic vascular patients (^28%).16
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Selected Abbreviations and Acronyms
CAD = coronaiy artery disease
CBS = cystathionine ß-synthase
Cl = confidence interval
MTHFR = 5,10-methylenetetrahydrofolate reductase
REGRESS = Regression Growth Evaluation Statin Study
Recently, Frosst and coworkers17 were able to identify 
a relatively common 677C-^T mutation in the MTHFR 
gene, which substituted a conserved alanine by a valine 
residue. Individuals who are homozygous for this muta­
tion often have elevated homocysteine concentra­
tions,17*18 especially in combination with a low folate 
status.19’20
In the present study, we investigated the prevalence of 
the 677C ^T  mutation in a well-defined population of 
735 male CAD patients and in 1250 population-based 
control subjects and assessed the association of this 
mutation to serum homocysteine concentration. Several 
studies have investigated the homozygous 677C—>T mu­
tation as a risk factor for CAD but with conflicting 
results,21'26 probably because of the relatively small 
numbers of individuals included in each study sepa­
rately. We therefore performed a meta-analysis of eight 
case-control studies reporting data on the MTHFR 
genotype distribution to estimate the relative risk of the 
homozygous (+ /+ ) genotype for CAD.
Methods
Study Population
We studied 735 male patients with angiographically assessed 
CAD enrolled in REGRESS, which was conducted under 
auspices of the Interuniversitary Cardiology Institute The 
Netherlands. REGRESS is a double-blind, placebo-controlled, 
multicenter trial designed to assess the effects of lipid-lowering 
therapy with pravastatin on progression and regression of CAD 
in 885 male patients with normal to moderately elevated serum 
cholesterol levels (4 to 8 mmol/L). The overall study design and 
inclusion criteria of patients have been described extensively,27
A large control group was constructed, consisting of individ­
uals recruited from several published28’29 and unpublished 
Dutch case-control studies (L.A.J.K., Van der Put, Den
Heijer, and Rosendaal, unpublished results), which resulted in 
a control group consisting of 1250 unrelated population-based 
control subjects. All 677C-*T mutation analyses were per­
formed in our laboratory.
For a summary quantitative risk assessment of the 677C—>T 
mutation in CAD, we evaluated eight international case- 
control studies,21"26-29 including the present one. In this analy­
sis, we confined ourselves to case-control studies in which 
MTHFR genotype distributions among both CAD patients and 
control subjects either were given or could be calculated from 
their data. We calculated the M THFR genotype distribution 
and odds ratios of the (+ /+ )  genotype for CAD in each study 
separately and for all studies combined.
MTHFR Genotype Analysis
Genomic DNA was extracted from peripheral blood lympho­
cytes by standard procedure, and mutation analysis was per­
formed essentially as described by Frosst et al.17 Electrophore­
sis in a 4% agarose gel followed by ethidium bromide staining 
and UV illumination allowed detection of mutated alleles.
Homocysteine Determination
After an overnight fast, blood was drawn from the CAD 
patients for an assessment of fasting homocysteine concentra­
T a b l e  1. Distribution of 677C—»T MTHFR Variant 
Among Patients With CAD and Control Subjects
CAD Patients 
(n=735), n (%)
Control Subjects  
(n=1250), n (%)
Odds Ratio 
(95% Cl)
+ / + 70 (9.5) 106(8.5) 1.21 (0.87-1.68)
+ / - 328 (44.6) 527 (42.2) 1.14(0.94-1.38)
337 (45.9) 617(49.4) 1.0*
‘ Reference category: odds ratio=1.0.
tions, and serum was stored at -70°C until analysis. Homocys­
teine concentrations were determined by high-performance 
liquid chromatography with use of a 150x4.6-mm Hypersil 
ODS column in a high-performance liquid chromatography 
analyzer (Thermo Separation Products) after the thiol groups 
were bound to a fluorescent label (SBD-F).30
Statistical Analysis
Odds ratios and 95% CIs were calculated as an estimate of 
the relative risk of the different genotypes in CAD.31 Differ­
ences in genotype distributions were calculated by x 2 analysis. 
To assess the relationship between the 677C—»T transition and 
homocysteine concentrations, we calculated median homocys­
teine concentrations in different genotype groups. Differences 
between homocysteine concentrations in these genotype 
groups were assessed by one-way ANOVA, followed by pair­
wise t tests on log-transformed data. All probability values are 
two-tailed, and a value of P < .05 was considered statistically 
significant,
R esults  
MTHFR Genotype Analysis
The overall frequency for the (+) allele was 31.8% 
among patients and 29.5% among control subjects. The 
numbers of individuals homozygous for the 677C—»T 
transition were 70 of 735 CAD patients (9.5%) versus 
106 of 1250 controls (8.5%; Table 1). The genotype 
distributions in both groups of individuals are consistent 
with those calculated from the Hardy-Weinberg equilib­
rium. The odds ratios as an estimate of the relative risk 
of the (47+) and (+ /- )  genotypes relative to the risk of 
the {—/ —) genotype for CAD were 1.21 and 1/14, 
respectively (Table 1). We also assessed the relative risk 
of the (+ /+ ) genotype in relation to the risk of individ­
uals with both other genotypes. In this model, the risk of 
the homozygous (+/+) genotype in CAD was 1.14 (95% 
Cl, 0.83 to 1.56).
Association Genotype and Total Homocysteine
Homocysteine concentrations were measured in 515 
of 735 CAD patients. The numbers of individuals in the 
three different MTHFR genotype groups in this subset 
of individuals were 51 (9.9%), 233 (45.2%), and 231 
(44.9%) for the (+/+), (+ /- )  and ( - / - )  genotype, 
respectively, which are not substantially different from 
the MTHFR genotype distribution observed in the en­
tire patient group (x2= 0.137, P=NS). As homocysteine 
concentrations in the different genotype groups showed 
a skewed distribution (data not shown), homocysteine 
concentrations are expressed in median (range) values. 
Individuals with the homozygous (+ /+ ) genotype have 
the highest homocysteine concentrations and (—/—) 
individuals have the lowest, whereas heterozygous 
(+ /“ ) individuals have intermediate homocysteine lev­
els, Both homozygotes (+ /+) and heterozygotes (4 7 -)  
have significantly elevated homocysteine concentrations
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T a b le  2. Association Between MTHFR Genotype and 
Fasting Serum Homocysteine Concentrations in 
CAD Patients
Study
Homocysteine concentrations are expressed as median values, 
is given in parentheses.
*P<.001 (ANOVA with log-transformed data). 
fP < .0 0 2  (t test) for + / +  vs + / -  and - / -  genotypes.
¿P<.05 [t test) for + / -  vs genotype.
Range
compared with (—/—) individuals, demonstrating a sig­
nificant effect of the homozygous (+/+) as well as 
heterozygous ( + / - )  genotype on homocysteine levels 
(Table 2).
We also assessed the MTHFR genotype distribution 
in different homocysteine strata (Fig 1). The frequency 
of the homozygous 677C—>T mutation showed a gradual 
increase from 4% in the lowest homocysteine stratum 
(homocysteine <10 ¿xmol/L) to 24% in the highest 
stratum (homocysteine >18 /xmol/L), again indicating 
the association between homocysteine concentrations 
and the homozygous (+ /+ ) genotype.
Thermolabile MTHFR in CAD
For a summary estimate of the relative risk of the 
homozygous (+ /+ ) genotype, we performed a meta­
analysis of studies reporting data on the MTFIFR geno­
types in patients with CAD. In this analysis, we confined 
ourselves to case-control studies in which MTIiFR 
genotype distributions among CAD patients as well as 
control subjects either were given or could be calculated 
from their data. For each study, we calculated odds 
ratios and 95% CIs for the (+ /+) genotype relative to 
the ( - / - )  genotype separately (Fig 2). The combination 
of all studies reported yielded a patient group consisting 
of 2476 individuals (299 + /+ , 1097 + / - ,  and 1080 - / - )  
and a control group of 2481 individuals (257 +/+, 1090 
, and 1134 - / —). From the MTHFR genotype 
distribution in this combined study group, we calculated 
an odds ratio of 1.22 (95% Cl, 1.01 to 1.47) for the 
homozygous (+ /+ ) genotype and 1.06 (95% CI} 0.94 to 
1.19) for the heterozygous (+ /—) genotype, both relative 
to the (--/—) genotype. When the heterozygotes (+ /—)
u«Bauu
L.w
Cm
-/- 
□ +/- 
■ +/+
<10 > 10-12 >12-14 >14-16 >16-18 >18
Homocysteine strata (^imol/L)
F i g  1, MTHFR genotype distribution in different homocysteine 
strata. Serum homocysteine concentration is expressed in mi­
cromoles per liter. In each stratum, the total number of individ­
uals is set to 100%.
Mact al (20
Wückcn ei al. (22)
MTHFR Genotype
Fasting Homocysteine 
Concentration, ^moi/L*
Gallagher ct al. <Z3> 
Schmiu cl aV (24)
+/+ (n~51) 15.4 (8.7-56.9)1- Adams et al. (23)
+ /-  (n~233) 13.4 (7.0-42.9)* Izuiui et al. <26)
- / -  (n=231) 12.6 (6.5-30.2) Verhoefet al. (29)
KUiijmuns ec al (present)
Overall
o.i 1.0
Odds ratio (95 % Cl)
10
Fig 2. Odds ratios and 95% CIs for CAD associated with the 
(+ /+ ) genotype relative to the ( - / - )  genotype. Reference num­
ber of each study is given In parentheses.
and ( - / - )  individuals are combined, the odds ratio for 
CAD among those with the (+ /+ ) genotype was 1.19 
(95% Cl, 1.00 to 1.42),
Discussion
In this study, we showed a correlation between the 
677C—>T mutation in the MTHFR gene and homocys­
teine concentrations in which homozygous (+ /+) and 
even heterozygous (+ /—) individuals exhibited signifi­
cantly elevated homocysteine levels compared with 
(—/—) individuals. Furthermore, by combining all previ­
ously reported studies, we were able to demonstrate the 
significance of the homozygous (+ /+ ) genotype as a risk 
factor for CAD.
Many studies have explored the relationship between 
elevated homocysteine concentrations and an increased 
risk for atherosclerotic vascular disease.2-3*32-33 Recently, 
these studies have been summarized in a meta-analysis,1 
which led to the conclusion that elevations in homocys­
teine concentrations have to be considered as an inde­
pendent and graded risk factor for different categories of 
arterial occlusive diseases. Several clinical studies sup­
ported this conclusion by establishing a quantitative 
relationship between coronary occlusion and homocys­
teine levels.35*36 On the basis of a linear relationship 
between homocysteine and the risk of CAD, Boushey et 
al1 calculated an odds ratio for CAD of 1.6 (95% Cl, 1.4 
to 1.7) for a 5-/xmol/L increase in homocysteine concen­
trations. Accordingly, a risk of 1.12 can be calculated for 
a 1-jnmol/L increase in homocysteine. In our analysis of 
the association between MTHFR genotype and homo­
cysteine concentrations, we observed an increase in 
median homocysteine concentrations of 0.8 ¿unol/L for 
heterozygous (+ /" )  and 2.8 ^mol/L for homozygous 
(4-/+) individuals relative to (—/ - )  individuals, which 
equals a risk for CAD of 1.10 and 1.34 for the heterozy­
gotes ( + / - )  and homozygotes (+ /+ ), respectively, rel­
ative to the risk of (-7 —) individuals. These risk esti­
mates calculated are well in line with the odds ratios for 
the homozygous (+ /+ ) and heterozygous (+ /- )  geno­
types observed in the present study (Table 1).
The frequency of the homozygous (+/+) genotype 
varies between different populations. The effect of this 
mutation on homocysteine concentrations depends on 
study design, inclusion criteria, ethnic background, age, 
and vitamin intake of the population. Except for the
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study of Schmitz et al,24 all recent studies on this 
MTHFR variant and hyperhomocysteinemia38’19’21’29’37’38 
showed elevated homocysteine concentrations in ho­
mozygous (+ /+ ) individuals. The present study supports 
these observations and indicates again that the homozy­
gous (+ /+ ) genotype is associated with elevated homo­
cysteine concentrations (Table 2 and Fig 1). Folate 
status is considered an important environmental modu­
lator of homocysteine levels only in homozygous (+ /+) 
individuals.1^ 21 The effect of the homozygous (+ /+) 
genotype on homocysteine concentrations might there­
fore differ between separate studies as a result of a 
different intake of folate. A  possible adjustment for 
plasma folate could not be performed in this study, 
because blood folate levels were not determined.
In the present study, we were also able to demonstrate 
a statistically significant effect of the heterozygous (+ /—) 
genotype on homocysteine concentrations. This is in line 
with the results reported by Harmon et al,38 who ob­
served elevated plasma homocysteine concentrations in 
heterozygous (+ /—) individuals in the top 50% of the 
homocysteine distribution. On the basis of specific and 
residual MTHFR activities measured in isolated lym­
phocytes, this observation was not unexpected, because 
we have shown that heterozygous (47*-*) individuals 
have significantly decreased specific and residual 
MTHFR activities compared with nonaffected (—/—) 
individuals.18-20 MTHFR-dependent homocysteine rem­
ethylation, in which 5-methyltetraliydrofolate (the prod­
uct of the reaction catalyzed by MTHFR) serves as 
methyl donor, is present in nearly every cell of the 
human body. Therefore, any significantly deleterious 
effect in MTHFR enzyme activity will be reflected in 
elevation of homocysteine concentration in these cells. 
Previous studies were unable to detect an effect of the 
heterozygous (+ /—) genotype on homocysteine concen­
trations, probably because of the relatively limited num­
ber of individuals included in those studies,
Kang et al5 were the first to report on a thermolabile 
MTHFR variant in two patients with CAD and hyper­
homocysteinemia. Subsequent studies by the same 
group14J5>39 showed an association between this thermo­
labile MTHFR and (the severity of) CAD. In a large 
study among CAD patients and healthy control subjects, 
Kang et al5 detected thermolabile MTHFR in 36 of 212 
cases (17%) versus 10 of 202 control subjects (5%).14 In 
the present study, we observed a much lower frequency 
of the thermolabile (+ /+ ) genotype among Dutch CAD 
patients and a higher frequency among Dutch popula­
tion-based control subjects. Several possible explana­
tions for this phenomenon should be considered. In the 
study by Kang et al,5 the frequency of thermolabile 
MTHFR was assessed biochemically and was not based 
on genotyping of the 677C—>T mutation. Because of the 
wide range in MTHFR activities in homozygous (+ /+) 
and heterozygous (+ /—) individuals,18-20 some individu­
als with a biochemically determined thermolabile 
MTHFR might not have been homozygotes (+ /+), but 
heterozygotes (+ /—) for the thermolabile allele or car­
riers for other mildly defective MTHFR alleles. In 
addition, Kang et al used in their studies a control group 
consisting of healthy controls with no history or clinical 
evidence of arterial occlusive disease. In our study, 
control subjects were recruited from the general popu­
lation, possibly including individuals with a positive
history of CAD, which may dilute an eventual effect of 
the homozygous (47+) genotype.
For a summary estimation of the relative risk of the 
homozygous (47+) genotype, we analyzed eight differ­
ent case-control studies presenting data on the MTHFR 
genotype distribution in CAD patients. From these 
studies,21-26*29 only an Irish study23 observed a significant 
odds ratio for the homozygous (+ /+ ) genotype in CAD, 
In all other studies, the odds ratios for the homozygous 
(+ /+ ) genotype were not significantly increased. By 
combining all studies, we were able to calculate a 
significant odds ratio of 1.22 (95% Cl, 1.01 to 1.47) for 
the homozygous (+ /+ ) genotype relative to the ( - / - )  
genotype in CAD, an odds ratio comparable to that 
obtained in the present study on the risk of thermolabile 
MTHFR in REGRESS. This overall result indicates that 
the thermolabile (+ /+ ) genotype itself is a modest but 
significant genetic risk factor for CAD, a risk that is 
likely modulated by environmental factors, especially 
folate status.18-21
In conclusion, we demonstrated for the first time, that 
both homozygotes (+ /+) and heterozygotes (+ /—) for 
the 677C-*T mutation in the MTHFR gene have signif­
icantly elevated homocysteine concentrations relative to 
( - / - )  individuals. The odds ratios observed for both 
(+ /+ ) and (4-/-) genotypes for CAD are graded and in 
concordance with the risk calculated from a large quan­
titative study on homocysteine as a risk factor for CAD. 
By performing a meta-analysis, we were able to show 
that the homozygous (+/+) genotype is a genetic risk 
factor for CAD.
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